These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 20473900)

  • 21. Dual inhibition of αV integrins and Src kinase activity as a combination therapy strategy for colorectal cancer.
    Jia J; Starodub A; Cushman I; Liu Y; Marshall DJ; Hurwitz HI; Nixon AB
    Anticancer Drugs; 2013 Mar; 24(3):237-50. PubMed ID: 23275294
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lyn kinase mediates cell motility and tumor growth in EGFRvIII-expressing head and neck cancer.
    Wheeler SE; Morariu EM; Bednash JS; Otte CG; Seethala RR; Chiosea SI; Grandis JR
    Clin Cancer Res; 2012 May; 18(10):2850-60. PubMed ID: 22490227
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of c-Src as a potential therapeutic target for gastric cancer and of MET activation as a cause of resistance to c-Src inhibition.
    Okamoto W; Okamoto I; Yoshida T; Okamoto K; Takezawa K; Hatashita E; Yamada Y; Kuwata K; Arao T; Yanagihara K; Fukuoka M; Nishio K; Nakagawa K
    Mol Cancer Ther; 2010 May; 9(5):1188-97. PubMed ID: 20406949
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dasatinib, a multi-kinase inhibitor increased radiation sensitivity by interfering with nuclear localization of epidermal growth factor receptor and by blocking DNA repair pathways.
    Raju U; Riesterer O; Wang ZQ; Molkentine DP; Molkentine JM; Johnson FM; Glisson B; Milas L; Ang KK
    Radiother Oncol; 2012 Nov; 105(2):241-9. PubMed ID: 23010482
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Peptidomimetic Src/pretubulin inhibitor KX-01 alone and in combination with paclitaxel suppresses growth, metastasis in human ER/PR/HER2-negative tumor xenografts.
    Anbalagan M; Ali A; Jones RK; Marsden CG; Sheng M; Carrier L; Bu Y; Hangauer D; Rowan BG
    Mol Cancer Ther; 2012 Sep; 11(9):1936-47. PubMed ID: 22784709
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of Src kinase inhibition induced by dasatinib in non-small cell lung cancer cell lines treated with cisplatin.
    Ceppi P; Papotti M; Monica V; Lo Iacono M; Saviozzi S; Pautasso M; Novello S; Mussino S; Bracco E; Volante M; Scagliotti GV
    Mol Cancer Ther; 2009 Nov; 8(11):3066-74. PubMed ID: 19861409
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel mechanism for obesity-induced colon cancer progression.
    Birmingham JM; Busik JV; Hansen-Smith FM; Fenton JI
    Carcinogenesis; 2009 Apr; 30(4):690-7. PubMed ID: 19221001
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Opposite angiogenic outcome of curcumin against ischemia and Lewis lung cancer models: in silico, in vitro and in vivo studies.
    Fan S; Xu Y; Li X; Tie L; Pan Y; Li X
    Biochim Biophys Acta; 2014 Sep; 1842(9):1742-54. PubMed ID: 24970744
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dasatinib is synergistic with cetuximab and cisplatin in triple-negative breast cancer cells.
    Kim EM; Mueller K; Gartner E; Boerner J
    J Surg Res; 2013 Nov; 185(1):231-9. PubMed ID: 23899511
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of Src family kinases with dasatinib blocks migration and invasion of human melanoma cells.
    Buettner R; Mesa T; Vultur A; Lee F; Jove R
    Mol Cancer Res; 2008 Nov; 6(11):1766-74. PubMed ID: 19010823
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells.
    Pichot CS; Hartig SM; Xia L; Arvanitis C; Monisvais D; Lee FY; Frost JA; Corey SJ
    Br J Cancer; 2009 Jul; 101(1):38-47. PubMed ID: 19513066
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel C6-substituted 1,3,4-oxadiazinones as potential anti-cancer agents.
    Alam MM; Lee SC; Jung Y; Yun HJ; Min HY; Lee HJ; Pham PC; Moon J; Kwon DI; Lim B; Suh YG; Lee J; Lee HY
    Oncotarget; 2015 Dec; 6(38):40598-610. PubMed ID: 26515601
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Target modulation by a kinase inhibitor engineered to induce a tandem blockade of the epidermal growth factor receptor (EGFR) and c-Src: the concept of type III combi-targeting.
    Rao S; Larroque-Lombard AL; Peyrard L; Thauvin C; Rachid Z; Williams C; Jean-Claude BJ
    PLoS One; 2015; 10(2):e0117215. PubMed ID: 25658745
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of Src phosphorylation alters metastatic potential of osteosarcoma in vitro but not in vivo.
    Hingorani P; Zhang W; Gorlick R; Kolb EA
    Clin Cancer Res; 2009 May; 15(10):3416-22. PubMed ID: 19447875
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dasatinib: BMS 354825.
    Drugs R D; 2006; 7(2):129-32. PubMed ID: 16542059
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients.
    Lu KV; Zhu S; Cvrljevic A; Huang TT; Sarkaria S; Ahkavan D; Dang J; Dinca EB; Plaisier SB; Oderberg I; Lee Y; Chen Z; Caldwell JS; Xie Y; Loo JA; Seligson D; Chakravari A; Lee FY; Weinmann R; Cloughesy TF; Nelson SF; Bergers G; Graeber T; Furnari FB; James CD; Cavenee WK; Johns TG; Mischel PS
    Cancer Res; 2009 Sep; 69(17):6889-98. PubMed ID: 19690143
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases.
    Liu Y; Karaca M; Zhang Z; Gioeli D; Earp HS; Whang YE
    Oncogene; 2010 Jun; 29(22):3208-16. PubMed ID: 20383201
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeted inhibition of Src kinase with dasatinib blocks thyroid cancer growth and metastasis.
    Chan CM; Jing X; Pike LA; Zhou Q; Lim DJ; Sams SB; Lund GS; Sharma V; Haugen BR; Schweppe RE
    Clin Cancer Res; 2012 Jul; 18(13):3580-91. PubMed ID: 22586301
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dietary-induced ERbeta upregulation counteracts intestinal neoplasia development in intact male ApcMin/+ mice.
    Barone M; Tanzi S; Lofano K; Scavo MP; Pricci M; Demarinis L; Papagni S; Guido R; Maiorano E; Ingravallo G; Comelli MC; Francavilla A; Di Leo A
    Carcinogenesis; 2010 Feb; 31(2):269-74. PubMed ID: 19945967
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Curcumin enhances the effects of 5-fluorouracil and oxaliplatin in mediating growth inhibition of colon cancer cells by modulating EGFR and IGF-1R.
    Patel BB; Sengupta R; Qazi S; Vachhani H; Yu Y; Rishi AK; Majumdar AP
    Int J Cancer; 2008 Jan; 122(2):267-73. PubMed ID: 17918158
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.